Meddenovo Drug Design
Lyon
About Meddenovo Drug Design
Meddenovo is an AI company pioneering the design of next-generation peptide therapeutics. Our platform creates novel cyclic peptides from scratch, combining advanced artificial intelligence with deep molecular understanding. These molecules can reach complex targets that small molecules or antibodies cannot, offering new possibilities for treating cancer and other diseases. We bring together science, computation, and creativity to design precise, stable, and effective candidates within weeks instead of months. Our technology is already being applied in collaboration with leading pharmaceutical partners to accelerate discovery and reduce development risk. Meddenovo’s mission is to make intelligent drug design accessible to every scientist, turning complex discovery processes into simple, insightful decisions that bring better medicines to patients faster.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.1M
- Funding stage: Seed
- Last round: Seed (Jan 2025)
- Website: meddenovo.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biopharma, Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/meddenovo-drug-design-92145 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.